



Compounds that exhibit anti-RSV activity are disclosed in WO- 2016/174079.

Summary

In one aspect, there is provided a compound of formula (I), including any stereochemically isomeric form thereof, wherein



including any stereochemically isomeric form thereof, wherein



n is 1;

X¹ and X² are selected from X¹ is CH and X² is CH,

or X¹ is N and X² is CH,

or X¹ is CH and X² is N;

R¹ is CH₃ or CH₂CH₃;

R² is hydrogen, halo or C₁₋₄alkyl;

R³ is halo;

R⁴ is C₁₋₆alkyl; C₃₋₆cycloalkyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each individually selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, and hydroxy;

R⁵ is hydrogen or C₁₋₄alkyl;

R⁶ is hydroxy;

cyano;

C₁₋₄alkyl substituted with hydroxy, -(CO)-NR¹⁰R¹¹ or -O-(CO)-NR¹⁰R¹¹;

-(CO)-NR¹⁰R¹¹;

-(CO)-NR⁹-SO₂-R⁸;

-(CO)-NR⁹-(CO)-SO₂-R⁸;

-(CO)-Heterocycle;

- (CO)-NR⁹-Heterocycle;
- O-(CO)-NR¹⁰R¹¹;
- NR⁹-(CO)-C₁₋₄alkyl;
- NR⁹-(CO)-C₃₋₆cycloalkyl;
5 - NR⁹-(CO)-O-R⁸;
- NR⁹-(CO)-NR⁹-R⁸;
- NR⁹-SO₂-R⁸;
- NR⁹-(P=O)-di(C₁₋₄alkyl);
- SO₂-R⁸;
10 - SO₂-NR¹⁰R¹¹;
- SO₂-NR⁹-(CO)-R⁸; or
Heteroaryl;

R⁷ is hydrogen, halo, C₁₋₄alkyl or -(CO)-NR¹⁰R¹¹;

R⁸ is C₁₋₄alkyl, polyhaloC₁₋₄alkyl, or C₃₋₆cycloalkyl;

each R⁹ is independently selected from hydrogen or C₁₋₆alkyl;

R¹⁰ and R¹¹ are each independently selected from hydrogen; CN; C₁₋₄alkyl; C₃₋₆alkenyl;
polyhaloC₁₋₄alkyl; C₃₋₆cycloalkyl; C₃₋₆cycloalkyl substituted with C₁₋₄alkyl;
or C₁₋₄alkyl substituted with hydroxy or cyano;

Heterocycle is pyrrolidinyl or oxetanyl; and

Heteroaryl is 3-oxo-2,3-dihydro-1,2-oxazolyl, or tetrazolyl, wherein each Heteroaryl is
optionally substituted with one or two substituents each independently
selected from C₁₋₄alkyl, halo, amino, and aminocarbonyl;

provided that when R⁶ is -NR⁹-(CO)-C₃₋₆cycloalkyl then X¹ is CH and X² is CH;
or a pharmaceutically acceptable acid addition salt thereof.

In another aspect, there is provided a pharmaceutical composition comprising a
pharmaceutically acceptable carrier and a therapeutically active amount of a compound as
defined herein.

In another aspect, there is provided a process for preparing a pharmaceutical composition
as defined herein wherein a therapeutically active amount of a compound as defined herein
is intimately mixed with a pharmaceutically acceptable carrier.


In another aspect, there is provided a compound as defined herein for use as a medicine.

In another aspect, there is provided a compound as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of a respiratory syncytial virus infection.


5 In another aspect, there is provided use of a compound of formula (I) as defined herein in the manufacture of a medicament for the treatment of a respiratory syncytial virus (RSV) infection.

Detailed description of the Invention

10 The present invention relates to compounds of formula (I)



including any stereochemically isomeric form thereof, wherein



n is 1 or 2;

X¹ and X² are selected from X¹ is CH and X² is CH,
 or X¹ is N and X² is CH,
 or X¹ is CH and X² is N;

R¹ is CH₃ or CH₂CH₃;

R² is hydrogen, halo or C₁₋₄alkyl;

R³ is halo;

R⁴ is C₁₋₆alkyl; C₃₋₆cycloalkyl; phenyl; phenyl substituted with 1, 2 or 3 substituents
 each individually selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, and hydroxy;

R⁵ is hydrogen or C₁₋₄alkyl;

R⁶ is hydroxy;


cyano;

C₁₋₄alkyl substituted with hydroxy, -(CO)-NR¹⁰R¹¹ or -O-(CO)-NR¹⁰R¹¹;


- 5
- (CO)-NR¹⁰R¹¹;
 - (CO)-NR⁹-SO₂-R⁸;
 - (CO)-NR⁹-(CO)-SO₂-R⁸;
 - (CO)-Heterocycle;
 - (CO)-NR⁹-Heterocycle;
 - O-(CO)-NR¹⁰R¹¹;
 - NR⁹-(CO)-C₁₋₄alkyl;

Claims

1. A compound of formula (I), including any stereochemically isomeric form thereof, wherein



including any stereochemically isomeric form thereof, wherein



n is 1;

X¹ and X² are selected from X¹ is CH and X² is CH,

or X¹ is N and X² is CH,

or X¹ is CH and X² is N;

R¹ is CH₃ or CH₂CH₃;

R² is hydrogen, halo or C₁₋₄alkyl;

R³ is halo;

R⁴ is C₁₋₆alkyl; C₃₋₆cycloalkyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each individually selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, and hydroxy;

R⁵ is hydrogen or C₁₋₄alkyl;

R⁶ is hydroxy;

cyano;

C₁₋₄alkyl substituted with hydroxy, -(CO)-NR¹⁰R¹¹ or -O-(CO)-NR¹⁰R¹¹;

-(CO)-NR¹⁰R¹¹;

-(CO)-NR⁹-SO₂-R⁸;

-(CO)-NR⁹-(CO)-SO₂-R⁸;

-(CO)-Heterocycle;

-(CO)-NR⁹-Heterocycle;

-O-(CO)-NR¹⁰R¹¹;

-NR⁹-(CO)-C₁₋₄alkyl;

-NR⁹-(CO)-C₃₋₆cycloalkyl;

-NR⁹-(CO)-O-R⁸;

-NR⁹-(CO)-NR⁹-R⁸;

-NR⁹-SO₂-R⁸;

5 -NR⁹-(P=O)-di(C₁₋₄alkyl);

-SO₂-R⁸;

-SO₂-NR¹⁰R¹¹;

-SO₂-NR⁹-(CO)-R⁸; or

Heteroaryl;

10 R⁷ is hydrogen, halo, C₁₋₄alkyl or -(CO)-NR¹⁰R¹¹;

R⁸ is C₁₋₄alkyl, polyhaloC₁₋₄alkyl, or C₃₋₆cycloalkyl;

each R⁹ is independently selected from hydrogen or C₁₋₆alkyl;

R¹⁰ and R¹¹ are each independently selected from hydrogen; CN; C₁₋₄alkyl; C₃₋₆alkenyl;

polyhaloC₁₋₄alkyl; C₃₋₆cycloalkyl; C₃₋₆cycloalkyl substituted with C₁₋₄alkyl;

15 or C₁₋₄alkyl substituted with hydroxy or cyano;

Heterocycle is pyrrolidinyl or oxetanyl; and

Heteroaryl is 3-oxo-2,3-dihydro-1,2-oxazolyl, or tetrazolyl, wherein each Heteroaryl is

optionally substituted with one or two substituents each independently

selected from C₁₋₄alkyl, halo, amino, and aminocarbonyl;

20 provided that when R⁶ is -NR⁹-(CO)-C₃₋₆cycloalkyl then X¹ is CH and X² is CH;

or a pharmaceutically acceptable acid addition salt thereof.

2. The compound as claimed in claim 1 wherein X¹ is CH and X² is CH.

25 3. The compound as claimed in claim 1 wherein X¹ is N and X² is CH, or X¹ is CH and X² is N.

4. The compound as claimed in any one of claims 1 to 3 wherein radical A is of formula (a-1).

30

5. The compound as claimed in any one of claims 1 to 4 wherein n is 1.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in any of claims 1 to 5.

35

7. The pharmaceutical composition according to claim 6, which further comprises another antiviral agent.

8. The pharmaceutical composition according to claim 7, wherein the other antiviral

agent is a RSV inhibiting compound.

9. A process for preparing a pharmaceutical composition as claimed in any one of claims 6 to 8 wherein a therapeutically active amount of a compound as claimed in any one of claims 1 to 5 is intimately mixed with a pharmaceutically acceptable carrier.
5
10. A compound as claimed in any one of claims 1 to 5 for use as a medicine.
11. A compound as claimed in any one of claims 1 to 5, or a pharmaceutical composition as claimed in any one of claims 6 to 8, for use in the treatment of a respiratory syncytial virus infection.
10
12. Use of a compound of formula (I) as defined in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a respiratory syncytial virus (RSV) infection.
15